Prescribing information and Adverse event reporting can be found at the bottom of the page
Endometrial hyperplasia is broadly defined as an excessive cellular proliferation leading to an increased volume of endometrial tissue. It is characterised by an increase in the endometrial gland-to-stroma ratio greater than 1:1.1
Endometrial hyperplasia is further classified as simple or complex, with or without atypia. This classification system is based on the complexity and crowding of the glandular architecture.1
The most common presenting symptom of endometrial hyperplasia is abnormal uterine bleeding, including:
However, endometrial hyperplasia can also be asymptomatic and can spontaneously regress without being detected.1
Oestrogen stimulates endometrial proliferation.1 A relative excess of oestrogen (exogenous or endogenous) compared with progesterone is considered to be one of the principle causes in endometrial hyperplasias.1
Key risk factors in post-menopausal women include:
Other risk factors include:
The only levonorgestrel intrauterine system licensed for four years for endometrial protection during oestrogen replacement therapy (ERT)1
The efficacy of Mirena® in preventing oestrogen-induced hyperplasia in peri-menopausal and postmenopausal women has been assessed in various studies.2,3
Mirena® significantly decreased menstrual bleeding compared with conventional oral hormone replacement therapy (P=0.001, N=200).2
Continuing Mirena® use during the transition from contraception to ERT has no known additional adverse events on the vaginal bleeding profile.5
The proportion of patients who had difficulties in coping with any items from the Women's Health Questionnaire decreased over time, during both the contraception and ERT phases with Mirena®.5
PP-PF-WHC-GB-1035 May 2022
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: pvuk@bayer.com
Further information is available on the “contact” tab at www.bayer.co.uk.